Introduction

The human skin is continuously damaged by various stressors caused by internal or external factors, such as exposure to ultraviolet (UV) rays and free radicals (1,2). Skin exposure to oxidative stress or UV radiation is known to cause aging and tumors (3,4). Meanwhile, the aged population with high UV ray accumulation rates has increased along with the increase in mean life expectancy, and the prevalence of malignant melanoma have therefore risen steadily as well (5,6).

Malignant melanoma comprises 4% of all skin cancer cases, but accounts for 80% of the deaths caused by skin cancer; when it metastasizes, the 10-year survival rate is less than 10% (7,8). Malignant melanoma is difficult to treat through surgery, radiation therapy, or chemotherapy. Despite recent improvements in immunotherapy and target therapy, there is still a great deal of difficulty in treatment...
due to high cost and toxicity (9,10). As a result, researchers have been trying for decades to find new anti-cancer substances in herbs (11-13).

Ginseng is one of the most commonly used ingredients in traditional medicine, and it is widely used as a medicinal herb for various purposes in many Asian countries (14,15). Numerous studies have found ginseng to have many physiological and pharmacological effects, such as maintaining homeostasis and improving memory. Ginseng has especially reported to have anti-cancer effects for ovarian cancer, breast cancer, lung cancer, and so on (16-20).

Ginsenosides are among the components of ginseng that give ginseng its various pharmacological effects. More than 60 ginsenosides are known, and Rg3 is a ginsenoside that has been reported to have multiple pharmacological and physiological effects (21-23). It has especially been noted to exert anti-cancer effects such as apoptosis induction and anti-proliferative, anti-metastatic, and anti-angiogenetic effects (24-29). Research on malignant melanoma has reported that Rg3 exerted apoptotic and anti-metastatic effects on B16F10 melanoma cells (30,31). However, B16F10 melanoma cells are a cell strain originating from mice, and studies on the anti-cancer effects of Rg3 on melanoma cells originating from humans have been rarely reported. This study, therefore, investigated A375.S2, a melanoma cell line originating from humans that has not been studied previously, and we examined whether the ginsenoside Rg3 induced apoptosis in A375.S2 cells and if so, through which signaling pathways.

The overall structure of this study is as follows: first, this study investigated the cell viability, cell morphology, colony formation ability, and migration of A375.S2 cells after treatment with Rg3. In order to determine whether apoptosis occurred when A375.S2 cells were treated with Rg3, a flow cytometric assay was conducted, western blotting was conducted for apoptotic proteins, and an immunocytochemical analysis was conducted. Finally, the study measured cell viability after treatment with inhibitors of various kinases that are known to be involved in apoptosis to determine which signaling pathway induced apoptosis.

**Methods**

**Reagents and materials**

The ginsenoside Rg3 was purchased from NPC & BioTech (Daejon, Korea). The Rg3 was dissolved in dimethyl sulfoxide (DMSO, 5 mg/mL) and stored at -80 °C. Specific kinase inhibitors, PD98059, SB203580, and SP600125, were purchased from Thermo Fisher Scientific (Pittsburgh, PA, USA).

**Cell culture**

A375.S2 melanoma cells were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in minimum essential medium containing 10% fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 µg/mL of streptomycin in an incubator with 5% CO2 at 37 °C.

**Effects of Rg3 on A375.S2 cells**

**Cell viability**

A375.S2 cells were treated with Rg3, and a methyl thiazol tetrazolium (MTT) assay was conducted to investigate cell viability. First, the A375.S2 cells were seeded at 1×10^4 per well into 96 wells, stored for 24 hours at 37 °C in the incubator, and then treated with different Rg3 concentrations (0, 10, 20, 40, 60, and 100 μM). After 24 hours, 10 μL of 5 mg/mL MTT was put into the 96 wells for 3 hours at 37 °C for the MTT assay. The culture medium was completely removed and 100 μL of DMSO was added. Light was blocked out and the wells were put on an orbital shaker for 5 minutes. The absorbance at optical density (OD) 570 nm was measured.

**Cell morphology**

A375.S2 cells were seeded at 5×10^4 per well into 12 wells, stored for 24 hours at 37 °C in the incubator, and then treated with different Rg3 concentrations (0, 10, 20, and 40 μM). The different cell shapes at different concentrations were observed using a microscope and photographed.

**Colony formation ability**

A375.S2 cells were seeded at 1×10^3 per well into 24 wells and stored for 24 hours. Then, with 5% FBS, they were treated with different Rg3 concentrations (0, 10, 20, and 40 μM). The different colony shapes at different concentrations were observed using a microscope and photographed.
Cell migration ability
A wound healing assay was conducted to investigate A375.S2 cell migration after Rg3 treatment. A375.S2 cells were seeded at 5×10^5 per well into 6 wells, stored for 24 hours, and cultured into monolayer cells. Then, the center was scratched using a 200 μL pipette tip to make a clean wound area, and washed with Hank's Balanced Salt Solution (Gibco-Invitrogen, Carlsbad, CA, USA). Then, with 5% FBS, they were treated with 20 μM Rg3, and observed after 24–72 hours using a microscope and photographed. Using ImageJ (National Institutes of Health, Bethesda, MD, USA), the wound distance was measured and quantified.

Confirmation of apoptosis
Flow cytometry assay
Apoptosis was confirmed using an annexin V-FITC/PI apoptosis detection kit (BD Pharmingen, San Diego, CA, USA). A375.S2 cells were seeded at 4×10^5 per well into 6 wells, stored for 24 hours, and treated with 40 μM Rg3. After 24 hours, the cells were sampled and stained with annexin V and propidium iodide (PI). The sampled cells were resuspended in 1× binding buffer at a concentration of 1×10^6 cells/mL. Then, 100 μL was removed into a 5-mL tube and mixed with 5 μL of annexin V and 4 μL of PI at room temperature for 15 minutes. Subsequently, 400 μL of 1× binding buffer was added to each tube and was measured using a flow cytometer within 1 hour.

Western blot
A375.S2 cells were seeded at 1×10^5 per well into 6 wells, stored for 24 hours, and treated with different Rg3 concentrations (0, 5, 10, 20, and 30 μM). After 24 hours, they were sampled and protein was obtained using a lysis buffer. The protein density was measured and equal amounts of protein were loaded onto an acrylamide gel to conduct a western blot test.

Immunocytochemical analysis
Cover slips were put into the well plates and coated with 5 μg/mL of fibronectin for 2 hours at 37 °C. A375.S2 cells were seeded at 5x10^4 per well into 12 wells, then treated with 20 μM Rg3 the next day. After 24 hours, 2 mL of 4% paraformaldehyde was put into each well and fixed for 15 minutes at room temperature. After they were washed 3 times with phosphate-buffered saline (PBS), they were blocked for a day at 4°C with 3% bovine serum albumin. Then, the primary antibody was put in for 2 hours to react. After washing 3 times with PBS, the secondary antibody was put in for 2 hours. Lastly, 4',6-diamidino-2-phenylindole (DAPI) was used to stain the samples for 5 minutes, washed using PBS, and observed by a microscope.

Signaling pathway for apoptosis
In order to identify which signaling pathways induced apoptosis, inhibitors of 3 types of kinases known to be involved in apoptosis were prepared: mitogen-activated protein/extracellular signal-related kinase inhibitor (MEK inhibitor: PD98059), p38 mitogen-activated protein kinase inhibitor (p38 MAPK inhibitor: SB203580), and c-Jun N-terminal protein kinase mitogen-activated protein kinase inhibitor (JNK MAPK inhibitor: SP600125).

A375.S2 cells were seeded at 1x10^4 per well into 96 wells and inhibitors of the 3 types of kinases (50 μM PD98059, 20 μM SB203580, 20 μM SP600125) were put in for 1 hour each, then treated with 20 μM Rg3. After storing for 24 hours in an incubator, MTT assay was conducted.

Statistical analysis
All data were analyzed using SPSS version 24.0 (IBM Corp., Armonk, NY, USA). The MTT assay measurements of cell viability and measurements of colony formation ability were analyzed using the Kruskal-Wallis test, while the measurements for cell migration ability and the MTT assay after using inhibitors were tested using the two-sample t-test. P values <0.05 were considered to indicate statistical significance.

Results
A375.S2 cell function changes after Rg3 treatment
Rg3 inhibits A375.S2 cell viability
Analyzing the cell viability with an MTT assay after treating A375.S2 cells with different Rg3 concentrations confirmed a significant decrease in cell viability for all Rg3 concentrations (10, 20, 40, 60, and 100 μM) compared to the control groups (P<0.05). The concentration of Rg3 inhibiting the 50% of cell viability (IC50) was 20 μM. An analysis of pairs of groups at successive intervals of Rg3 concentrations showed that groups treated with 40 μM Rg3 and 60 μM Rg3 did not have a significant difference (P<0.05), but all other such pairs showed a significant difference (Figure 1).
Rg3 changes A375.S2 cell morphology
A375.S2 cells treated with Rg3 changed to have a rounder shape as the Rg3 concentration increased. In addition, the number of cells decreased with Rg3 treatment (Figure 2).

Rg3 inhibits the colony formation ability of A375.S2 cells
When the colony formation ability of A375.S2 cells was analyzed 24 hours after treatment with different Rg3 concentrations, the colony formation ability was found to have decreased for all Rg3 concentration levels compared to the control group (P<0.05). No significant difference was found between the group treated with 20 μM Rg3 and the group treated with 40 μM Rg3 (P>0.05), while the difference between the group treated with 10 μM Rg3 and the group treated with 20 μM Rg3 was significant (P<0.05) (Figure 3).

Rg3 inhibits cell migration of A375.S2 cells
When the cell migration ability of A375.S2 cells was tested 72 hours after treatment with 20 μM Rg3, it was found that the cell migration ability decreased in the group treated with Rg3 compared to the control group (P<0.05) (Figure 4).

A375.S2 cell apoptosis after Rg3 treatment
Confirming apoptosis using a flow cytometric assay
When apoptosis was analyzed using a flow cytometric assay...
24 hours after A375.S2 cells were treated with 40 μM Rg3, a clear tendency for apoptosis was found in comparison to the control group (Figure 5).

Confirming apoptosis using Western blot
When western blotting was conducted 24 hours after A375.

Confirming apoptosis by an immunocytochemical analysis
When apoptosis was analyzed through an immunocytochemical

Figure 3 Colony formation ability of A375.S2 cells treated with Rg3 at various concentrations. Compared with the control group, colony formation ability decreased in all groups treated with Rg3 (P<0.05). (A) A375.S2 cells were treated with Rg3 at various concentrations and colonies were confirmed under a microscope after 24 hours (magnification, x40). (B,C) Compared with the control group, the colony formation ability of all the experimental groups decreased (n=14).

Figure 4 Cell motility of A375.S2 cells treated with Rg3. Compared with the control group, the cell motility of the experimental group decreased (P<0.05). (A) A scratch was made through the cell layer of the experimental group and the control group using a pipette tip, and cell motility was confirmed under a microscope after 72 hours (magnification, x40). (B) Compared with the control group, the cell motility of the experimental group decreased (n=12).
After A375.S2 cells were treated with 20 μM Rg3, the DAPI stain test found that the group treated with Rg3 showed a decrease in cell numbers compared to the control group. Bax accumulated, while the amount of Bcl-2 decreased (Figure 7).

**Confirmation of the signaling pathways that induce apoptosis**

**Involvement of MEK inhibitor in A375.S2 cell apoptosis through Rg3 treatment**

The A375.S2 cells were treated with 3 types of inhibitors—MEK inhibitor (PD98059), p38 MAPK inhibitor (SB203580), and JNK MAPK inhibitor (SP600125)—and then treated with 20 μM Rg3. An MTT assay was conducted to check cell viability, and the results showed a significant difference in the group with MEK inhibitor treatment compared to the group only treated with Rg3 (P<0.05). The groups treated with JNK MAPK inhibitor or

---

**Figure 5** After treatment with Rg3, apoptosis of A375.S2 cells was confirmed by flow cytometry. (A) Control; (B) Rg3 (40 μM) was administered. The Q1, and Q3 regions are the surviving cells, while the Q2, and Q4 regions indicate cells that underwent apoptosis.

**Figure 6** After treatment with Rg3, the apoptosis of A375.S2 cells was confirmed by western blotting. As the concentration of Rg3 increased, Bax accumulated and the amount of Bcl-2 decreased, such that the Bax/Bcl-2 ratio increased.
p38 MAPK inhibitor did not show a significant difference compared to the group treated with only Rg3 (P>0.05) (Figure 8).

**Discussion**

Rg3 is a ginsenoside found in ginseng that belongs to the class of saponins, and it has been reported to have multiple pharmacological and physiological effects, including anti-cancer effects. Zhang et al. reported Rg3 to be effective against lung cancer (32), and Xu et al. reported that Rg3 inhibited the metastasis and growth of cancer in ovarian cancer (17,18). Yuan et al. reported that Rg3 induced apoptosis in colon cancer (19), and Qiu et al. reported that Rg3 induced apoptosis on cancer cells in leukemia (20).

Meanwhile, studies on malignant melanoma have reported that Rg3 exerted apoptotic and anti-metastatic effects on B16F10 melanoma cells (30,31). In a study conducted by Lee et al. in 2014, results of a cell viability test, TUNEL assay, and western blotting indicated that apoptosis occurred in B16F10 melanoma cells when treated with Rg3 (30). Subsequently, Lee et al. reported in their 2015 study, in which they assessed cell viability, cell morphology, cell migration, invasion ability, and colony formation ability, as well as performing a western blot analysis, that the MMP-13 protein was inhibited, confirming that Rg3...
inhibited the metastasis of B16F10 cells (31). However, B16F10 melanoma cells are a cell strain originating from mice, meaning that the results of Lee et al. have limitations in terms of clinical applicability. Shan et al. have reported that Rg3 inhibits proliferation of melanoma cells originating in humans (33). But other studies on melanoma cells originating in humans, to determine whether Rg3 has anti-cancer effects, and specifically whether Rg3 can induce apoptosis, have been rarely reported. Furthermore, research on the process of Rg3-induced apoptosis and the signaling pathways through which it is induced.

This study investigated the effects of Rg3 on A375. S2 cells, a melanoma cell line originating in humans that has not been studied previously. It examined whether Rg3 induced apoptosis and if so, through which signaling pathways. In order to conduct this research, the author planned a 3-step experiment. First, this study investigated the viability, morphology, colony formation ability, and migration of A375.S2 cells after treatment with Rg3 to see whether any functional changes occurred. An MTT assay found that all groups treated with Rg3 showed decreased cell viability compared to the control group; of particular note, the cell viability decreased by half when treated with Rg3 with a concentration between 20 and 40 μM. Furthermore, the cells changed from a flat form to a rounder shape as the Rg3 concentration increased and cell membrane blebbing occurred. Cell membrane blebbing is known to occur due to F-actin polymerization and actomyosin contractility during the execution phase of apoptosis (34,35). This serves as evidence of the involvement of Rg3 in cell morphology and its ability to induce apoptosis. In addition, a decrease in the number of cells was found, along with morphological changes, as the Rg3 concentration increased. This supports the results presented above regarding cell viability. Colony formation ability and cell migration ability are common characteristics visible in tumor cells, and were also inhibited by Rg3 treatment.

Second, in order to investigate whether apoptosis had taken place, a flow cytometric assay, western blot, and immunocytochemistry analysis were conducted. These 3 experiments all indicated that apoptosis occurred when the A375.S2 cells were treated with Rg3. Apoptosis can generally be divided into the mitochondria-dependent pathway (intrinsic pathway) and the death receptor-dependent pathway (extrinsic pathway) (36-38). The extrinsic cell death pathway is known to be associated with the Fas ligand that induces intracellular signaling and cleavage by attaching to the Fas receptor and activating caspase-8 (39,40). Furthermore, the mitochondria-dependent pathway and death receptor-dependent pathway are both controlled by Bcl-2 family proteins (41,42). The Bcl-2 family contains pro-apoptotic proteins, such as Bax, Bak, Bad, and Bcl-Xs, and anti-apoptotic proteins, such as Bcl-2, Bcl-XL, and Mcl-1 (43). The Bax/Bcl-2 ratio is an important factor in experimental conditions, as it determines whether apoptosis occurs or not (43). In this study, we found that Bax accumulated and Bcl-2 decreased through western blotting and immunocytochemical analysis. This can serve as a critical piece of evidence that Rg3 induces apoptosis.

Finally, the study used an MTT assay to evaluate A375. S2 cells that were treated with Rg3 after the administration of inhibitors of various kinases that are known to be involved in apoptosis. The viability of A375.S2 cells decreased when treated with Rg3 after a MEK inhibitor was administered. This suggests that apoptosis occurring after Rg3 treatment can be induced through the MEK signaling pathway, and serves as additional evidence that A375.S2 cells treated with Rg3 underwent apoptosis.

This study has some limitations in confirming the effect of the inhibitor without confirming the effect of activator treatment in the process of confirming apoptosis signaling pathway, and in that it requires further confirmation of other pathways such as nuclear factor kappa B (NF-kB). Despite these limitations, the results presented above, unlike those of previous studies that did not deal with human-originated A375.S2 melanoma cells, prove that Rg3 can induce apoptosis in human-derived cancer cells. This study is also valuable because it confirmed the relationship between apoptosis and the MEK signaling pathway. Based on these results, future research should analyze whether Rg3 has similar effects on other melanoma cells or has different effects on different types of melanoma cells. Furthermore, research should be conducted on whether Rg3 can treat melanoma cells injected into animals in vivo.

**Conclusions**

This study confirmed that Rg3, a major active ingredient of ginseng, affected the cell viability, morphology, colony formation ability, and cell migration ability and induced apoptosis in A375.S2 cells, a human-originated melanoma cell strain. Apoptosis was mediated by the MEK signaling pathway. In this study, we found that the ginsenoside Rg3 had an anti-cancer effect on malignant melanoma cells, and we made strides towards better understanding
the mechanism. With these results, if clinical studies on ginsenoside Rg3 are continued in the future, it is expected that Rg3 will be applied as an anti-cancer drug for malignant melanoma.

**Acknowledgements**

**Funding:** This study was supported by Medical Research Institute Grant [2015-11], Pusan National University Hospital.

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** This study is based on the experiments conducted in *vitro* using the cell line available for purchase. So no statement is required.

**References**


Cite this article as: Kim JH, Bae YC, Lee JW, Choi JS, Bae SH. Effects of ginsenoside Rg3 on apoptosis in A375.S2 melanoma cells. Transl Cancer Res 2018. doi: 10.21037/tcr.2018.11.15